Clinical trials: Placebo Response
Major Depressive Disorder
SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
This study will examine SPD489 in subjects aged 18-65 with major depressive disorder (MDD) who are taking certain types of antidepressants but continue to have residual depression symptoms.
- Trial name
- NCT01435759
- Testing
- Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg, Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg
- Where
- 82 sites in United States, Argentina and 3 more
- Volunteers
- 1,197 people
- Sponsor
- Shire
Asthma
Randomised Study Comparing the Effects of Inhaled FF/GW642444M Combination, FF and GW642444M on an Allergen Induced Asthmatic Response
We propose to use an inhaled allergen challenge model to explore the individual contributions of the components of a novel long-acting beta agonist/ inhaled corticosteroid combination product and its components on protection from…
- Trial name
- NCT01128595
- Testing
- FF/GW642444M, GW642444M, Fluticasone Furoate
- Where
- 4 sites in Australia, New Zealand and 1 more
- Volunteers
- 27 people
- Sponsor
- GlaxoSmithKline
Herpes Zoster, Fibrosis
Placebo Controlled Evaluation of the Cell Mediated Immune Response of Cirrhotic Subjects to Zostavax™
Study Design: Double-blinded, placebo controlled study of the efficacy of Zostavax in cirrhosis. Subjects will receive either Zostavax or placebo and will be followed for four months.
- Trial name
- NCT02958345
- Testing
- Zostavax
- Volunteers
- 28 people
- Sponsor
- Tulane University
Bacteremia
Study to Investigate the Safety, Tolerability, and Pharmacokinetics of DSTA4637S in Participants With Staphylococcus Aureus Bacteremia Receiving Standard-of-Care (SOC) Antibiotics
This is a Phase Ib, randomized double-blind, placebo-controlled multiple-ascending dose study to investigate the safety, tolerability, and pharmacokinetics of multiple doses of DSTA4637S when given in addition to…
- Trial name
- NCT03162250
- Testing
- DSTA4637S, SOC
- Where
- 16 sites in United States, South Korea and 1 more
- Volunteers
- 27 people
- Sponsor
- Genentech, Inc.
Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6
Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
The vast majority of serious clinical situations leading to intensive care (septic shock, polytrauma, acute cerebral aggression, major surgery) are characterized by significant systemic inflammation.
- Conditions
- Post-aggressive Immunosuppression, Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6, Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C
- Trial name
- INFINITY (NCT06694740)
- Testing
- Interferon Gamma 1-b
- Where
- 2 sites in France
- Volunteers
- 170 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Rheumatoid Arthritis
Evaluation of Effectiveness of Two Dosing Regimens of Fostamatinib Compared to Placebo in Patients With Rheumatoid Arthritis (RA) Who Are Taking Disease Modifying Anti-rheumatic Drug (DMARD) But Not Responding.
The purpose of the study is to evaluate the effectiveness of two dosing regimens of fostamatinib compared to placebo, in patients with rheumatoid arthritis (RA) who are taking disease modifying anti-rheumatic drug (DMARD) but not…
- Trial name
- OSKIRA - 2 (NCT01197534)
- Testing
- fostamatinib
- Where
- 149 sites in United States, Canada and 14 more
- Volunteers
- 913 people
- Sponsor
- AstraZeneca
Primary Dysmenorrhea
Manual Acupuncture for Primary Dysmenorrhea
Primary dysmenorrhea (PD) is a common complaint in menstruating women. Although nonsteroidal anti-inflammatory drug is an effective treatment, there are concerns about serious adverse events.
- Trial name
- NCT02783534
- Testing
- Verum acupuncture, Usual care
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Huazhong University of Science and Technology
Sepsis
ASpirin for Patients With SEPsis and SeptIc Shock
This Randomized, pragmatic, multicentric with blinding of patients and health professionals, intention-to-treat analysis has by primary endpoint to evaluate whether the aspirin use reduces the intensity of organic dysfunction…
- Trial name
- ASP-SEPSIS (NCT01784159)
- Testing
- Aspirin
- Where
- Brazil
- Volunteers
- 167 people
- Sponsor
- Federal University of São Paulo
Perioperative Pain
Dose-Response of Adenosine for Perioperative Pain
Adenosine A1 and A2 receptors are widely distributed in the brain and spinal cord and represent a non-opiate target for pain management.
- Trial name
- NCT00298636
- Testing
- adenosine
- Where
- 8 sites in United States
- Volunteers
- 160 people
- Sponsor
- Xsira Pharmaceuticals
Rheumatoid Arthritis
Efficacy Confirmation Trial of CDP870 as add-on Medication to Methotrexate (MTX) in Japanese Rheumatoid Arthritis (RA)
The objective of this trial is to investigate the efficacy (American College of Rheumatology 20% : ACR20) superiority of two dose regiments of CDP870 versus placebo in combination with MTX in active RA patients who have an…
- Trial name
- NCT00791999
- Testing
- CDP870 400mg, CDP870 200mg, CDP870 100mg
- Where
- 8 sites in Japan
- Volunteers
- 316 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
This phase II trial studies how well TPIV100 and sargramostim work in treating patients with HER2 positive, stage II-III breast cancer that has residual disease after chemotherapy prior to surgery.
- Conditions
- Breast Adenocarcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage IIA Breast Cancer AJCC v6 and v7, Stage IIB Breast Cancer AJCC v6 and v7
- Trial name
- NCT04197687
- Testing
- Multi-epitope HER2 Peptide Vaccine TPIV100, Pertuzumab, Sargramostim
- Where
- 30 sites in United States
- Volunteers
- 480 people
- Sponsor
- Academic and Community Cancer Research United
Healthy
Acute Effects of a Botanical Extract and Its Main Volatile Compound on Stress Response in Healthy Adults
The prevalence of stress in daily human life increase in the investigator's modern life style. Short stress, could be benefit for memory, but prolonged stress may conduct to disturbance in cardiovascular, neuroendocrine and…
- Trial name
- NCT04523870
- Testing
- Botanical extract, Main compound of the botanical extract
- Where
- France
- Volunteers
- 19 people, healthy volunteers welcome
- Sponsor
- Activ'inside
Cardiovascular Diseases, Heart Diseases
Conditioned Placebo Effects and Treatment of Hypertension
To compare the unconditioned and conditioned effects of placebo capsules in the treatment of patients with borderline hypertension (BH).
- Conditions
- Cardiovascular Diseases, Heart Diseases, Hypertension
- Trial name
- NCT00269269
- Testing
- antihypertensive drug
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Healthy
Influence of Tocolytical Medications on Hemodynamics (Central and Peripheral) and Vascular Function in a Pilot Study to Determine the Design of the Final Study and the Final Study Itself
This trial will consist of two parts: A pilot study in a three-way cross over trial to determine the highest well tolerated dose of Ritodrine (Pre-Par®), the impact of Atosiban (Tractocile®) on the hemodynamics and hence the…
- Trial name
- NCT00679705
- Testing
- Ritodrine, Atosiban
- Where
- Belgium
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- University Hospital, Ghent
Septic Shock
Acetyl-L-Carnitine in the Treatment of Septic Shock
This placebo-controlled study investigates acetyl-L-carnitine in the treatment of septic shock requiring vasopressors.
- Trial name
- ALC (NCT00592488)
- Testing
- Acetyl-L-Carnitine
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Vanderbilt University
Gastro Esophageal Reflux
A Placebo Controlled Trial With Baclofen for the Treatment of GERD Patients With Incomplete PPI Response
Reflux (acid and non-acid) mainly occurs during transient LES relaxations (TLESRs). The gamma-aminobutyric acid (GABA) receptor type B agonist baclofen was shown to inhibit TLESRs, thereby significantly decreasing acid reflux…
- Trial name
- NCT03835442
- Testing
- Baclofen
- Volunteers
- 60 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Rheumatoid Arthritis
A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve Adults With Early Active Rheumatoid Arthritis
This study is intended to evaluate the efficacy and safety of Certolizumab Pegol (CZP) in combination with Methotrexate (MTX) for inducing and sustaining clinical response in the treatment of Disease Modifying Antirheumatic Drug…
- Trial name
- C-early (NCT01519791)
- Testing
- Certolizumab Pegol, Methotrexate
- Where
- 178 sites in United States, Argentina and 20 more
- Volunteers
- 880 people
- Sponsor
- UCB Pharma SA
Coronavirus, COVID
A Phase 2 Study to Evaluate Axatilimab for Hospitalized Participants With Respiratory Involvement Secondary to COVID-19
This was a randomized, double-blind, placebo-controlled, 29-day study to assess the efficacy and safety of axatilimab plus standard of care (SOC), compared with placebo plus SOC, in participants with respiratory signs and…
- Conditions
- Coronavirus, COVID, ARDS, Cytokine Storm
- Trial name
- NCT04415073
- Testing
- SNDX-6352
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- Syndax Pharmaceuticals
Gram-Negative Bacterial Infections, Sepsis
A Randomised Trial on the Saftely and Efficacy of GR270774 in the Treatment of Gram-negative Sepsis in Adult
Sepsis sometimes occurs in people who have a serious infection. It is caused by toxic substances (toxins) from bacteria and other germs entering your bloodstream.
- Trial name
- NCT00563134
- Testing
- GR270774
- Where
- China
- Volunteers
- 1,800 people
- Sponsor
- Hospital Authority, Hong Kong
Rheumatoid Arthritis
Proof-of-Concept Study With BMS-817399 to Treat Moderate to Severe Rheumatoid Arthritis
The purpose of this study is to assess whether BMS-817399 in combination with Methotrexate is effective in treating moderate to severe rheumatoid arthritis.
- Trial name
- RA (NCT01404585)
- Testing
- BMS-817399
- Where
- 29 sites in United States, Argentina and 5 more
- Volunteers
- 123 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.